ЕМТРИЦИТАБІН/ТЕНОФОВІРУ ДИЗОПРОКСИЛУ ФУМАРАТ

Product Overview

About ЕМТРИЦИТАБІН/ТЕНОФОВІРУ ДИЗОПРОКСИЛУ ФУМАРАТ

ЕМТРИЦИТАБІН/ТЕНОФОВІРУ ДИЗОПРОКСИЛУ ФУМАРАТ is a prescription medication containing the active ingredients Tenofovir disoproxil and emtricitabine. It is used to treat HIV-1 infection in adults and pediatric patients 12 years of age and older, weighing at least 17 kg, in combination with other antiretroviral agents.

Key Benefits & Uses

• Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older, weighing at least 17 kg, in combination with other antiretroviral agents.
• Prevention of mother-to-child transmission of HIV-1 in pregnant women with HIV-1 in combination with other antiretroviral agents.
• Pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV-1 infection in adults and adolescents at high risk.

Active Ingredient & Action

Tenofovir disoproxil and emtricitabine work by inhibiting the replication of the HIV-1 virus. Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NtRTI) that blocks the action of the HIV-1 reverse transcriptase enzyme, while emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that also blocks the action of the HIV-1 reverse transcriptase enzyme. By inhibiting the replication of the HIV-1 virus, Tenofovir disoproxil and emtricitabine help to reduce the viral load and prevent the progression of HIV-1 infection.

Important Notes

It is essential to follow the recommended dosage and administration instructions provided by your healthcare provider. Do not take more or less of the medication than prescribed, and do not take it more frequently than directed. Inform your healthcare provider about any medical conditions, allergies, or medications you are taking before starting treatment with ЕМТРИЦИТАБІН/ТЕНОФОВІРУ ДИЗОПРОКСИЛУ ФУМАРАТ. Regular monitoring of your viral load and CD4 cell count is recommended to assess the effectiveness of the treatment and to make any necessary adjustments.